超出印刷页面|2021年12月20日

将Lara Sullivan带到Biopharma的道路

资料来源:生命科beplay老版学领导
Rob Wright Author Page

经过罗克赖特,主要编辑,生命科学领袖beplay老版
在推特上关注我@rfwrightlsl.

Lara Sullivan.
Lara Sullivan,M.D.,CEO,Pyxis肿瘤学

在采访Lara Sullivan,M.D.,Pyxis肿瘤科首席执行官,用于即将到来的功能beplay老版,我了解到我们有一个共同点。首先,我们都是医生的孩子。其次,我们的医师父亲都是美国公共卫生服务(USPHS)的一部分。“我的父母去了Med Scho学校的哥伦比亚,这就是为什么我出生在纽约市,”她解释道。随着对她父亲的医学院支付的USPH,他们将他送到一个农村地区努力偿还他的债务。这就是沙利文如何在宾夕法尼亚州罗切斯特和锡拉丘斯之间的纽约州纽约市北北端的北端,这是普恩燕的普恩·燕村的长大。“当我们在那里搬到那里时,每周三出版的当地报纸,有一个关于两名医生搬到城镇的医生,以及我父母的照片和我们四个孩子的照片。”根据沙利文的说法,当在一个小镇成长为医生父母的孩子时,每个人都知道你是谁。“我会去超市,并会遇到某人,不可避免地谈论我的父母如何照顾他们的一个亲戚会出现。”

虽然Sullivan赞赏她的医生父母在她所喜欢的小社区中的重要作用,但她在他们的医疗脚步上反抗。她继续研究比较文学作为康奈尔的本科文学,在沃尔街的银行支出三年。“我的第一项工作是瑞士信贷第一波士顿的分析师,我主要专注于医院和大学的医疗保健债券,”她回忆道。但在他们撤销分析师的前三个月内,只能雇用他们。然后他们放弃整个部门,但随后聘请了分析师。总的来说,沙利文说,在她第一个大学后工作的前六个月内,她被聘用了三次。“从我的角度来看,似乎非常不稳定,也许是通过反对,我已经过时地解雇了药物。”所以,她开始在贝尔维尤医院开始志愿者给药一个公平的摇晃,很快看到了吸引了她的父母的东西 - 对患者进行了差异。因此,她决定申请医学院。“但是,通过这一点,我认为,我有足够的商业知识,如果我成为一个练习医生,我可能对健康制度管理水平最有帮助。” She focused on applying to schools offering dual M.D./MBA programs, getting accepted into the University of Pennsylvania School of Medicine (Penn) and The Wharton School. “I did med school first, and then Wharton, which was like a complete re-education on the world of business.” Having grown up in rural upstate NY, Sullivan’s experience was, if you were a doctor, you practiced, that’s it. “I hadn’t been exposed to the notion that you could be an M.D. and/or a Ph.D. in a business role.” Her first Wharton summer internship was with McKinsey, and they put her in a Big Pharma women’s health strategy project around different women’s health markets. “It was so much fun getting to use my medical knowledge and business experience,” she recalls. Upon finishing the two programs, Sullivan knew she wanted to focus on business, so she opted not to do a medical residency, and instead went to work at McKinsey fulltime. “It was an incredibly intoxicating learning environment, because you got to see so many business problems in different settings.” And it was this that led her to join Pfizer in 2011. “One of my main clients was Wyeth R&D, and when the company was acquired by Pfizer, a lot of the people who opted to stay started contacting me asking if I was ready to come over, and I said, ’Absolutely.’” In addition to six years at Pfizer, Sullivan has served as the founder and founding president of SpringWorks Therapeutics (18beplay官网 ),管理她自己的咨询公司,并迅速纳入Pyxis肿瘤的第二次生物制药公司首席执行官(纳斯达克:Pyxs)。不要错过阅读这个CEO在建造她的第二件辉瑞衍生时的旅程订阅今天。